Acquisition
May 2026Eli Lilly acquired Engage Bio for up to $202M in cash, including upfront and milestone payments.
SourcemRNA Immunotherapies to Eliminate Cancer
Company research
Public company, workplace, funding, and market signals
Overview
Preclinical San Carlos biotech founded in 2021 that built the Tethosome platform for non-viral DNA medicines; acquired by Eli Lilly in 2026.
Primary product
Tethosome non-viral DNA medicine platform
Founded
2021
Headquarters
San Carlos, California, United States
Team size
1-10
Work style
Onsite
Industry
Biotechnology Research
Sub-industry
Genetic medicine / non-viral DNA delivery
Offices
San Carlos, CA (HQ)
Open Positions
0 jobs at Engage Bio
No open positions
Check back later for new openings